Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nineteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $176.77.

SRPT has been the subject of a number of research analyst reports. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Robert W. Baird cut their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Evercore ISI dropped their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target for the company. Finally, Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently modified their holdings of the stock. Manchester Capital Management LLC boosted its stake in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. boosted its stake in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank boosted its stake in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $36,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Up 1.7 %

Shares of SRPT opened at $107.12 on Thursday. The company has a 50-day simple moving average of $118.21 and a 200-day simple moving average of $123.95. The firm has a market capitalization of $10.23 billion, a P/E ratio of 85.70 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a 52 week low of $101.15 and a 52 week high of $173.25.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.